Human reprogramming trials launch — plus cracks in epigenetic clocks

Life Biosciences received FDA IND clearance in January 2026 for ER-100, a gene therapy delivering OSK Yamanaka factors to the optic nerve — the first human trial of partial cellular reprogramming. Initial cohort: up to 12 glaucoma patients and 6 with NAION, monitored for at least 5 years.
The company raised $80M in Series D financing to fund the Phase 1 eye trial and advance ER-300, a liver-targeting reprogramming program currently in preclinical development.
FDA is not approving the trial for "aging" — it is using disease-specific endpoints (glaucoma, NAION) and its new Plausible Mechanism Pathway, which may allow smaller cohorts based on mechanistic evidence. Successful results across ER-100 and ER-300 would demonstrate the platform can transfer between organs.
Nature's coverage of the trial notes monkey studies showed no tumor formation using OSK without c-Myc, but researchers caution that even partial reprogramming carries risk of cell identity loss if cells are pushed too far.
Japan approved the world's first two iPSC-based cell therapies, targeting heart failure and Parkinson's disease — a separate regulatory milestone advancing iPSC-derived medicine from research to approved treatment.
Stanford researchers identified a method to reverse age-related cartilage loss and regrow joint cartilage, a tissue type long considered unable to self-repair in adults.

Yale researchers tested 18 widely used epigenetic clocks using repeated biological samples from the same individuals and found biological age estimates fluctuate 5–10 years on average within a single day, with some clocks varying up to 40 years. Drivers include circadian rhythms and food intake.
The critical finding: technical reproducibility does not predict biological stability — a clock can be technically precise yet biologically noisy, making it difficult to distinguish genuine intervention effects from normal intraday variation in clinical trials.
A deep learning analysis of 143,642 UK Biobank participants showed that accelerated biological aging in specific organs, detected via imaging, precedes diagnoses of Alzheimer's, type 2 diabetes, and CKD — pointing toward organ-specific imaging biomarkers as a more stable alternative to methylation-based clocks.
The DO-HEALTH trial's combination of omega-3, vitamin D, and resistance training slowed epigenetic aging by approximately 3.8 months — with the combination outperforming any individual intervention. Context for the Yale reliability data: a 3.8-month effect size sits within the intraday noise range flagged by the Yale team, raising questions about how to interpret such results.

The UK's MHRA announced an investigation into peptide clinics making unauthorized medicinal claims for BPC-157, MOTS-C, and related compounds — the first formal regulatory action targeting the UK's peptide wellness sector.
The New Yorker published a longform examination of the self-injection trend, noting that BPC-157's primary research base is concentrated in studies co-authored by its own patent holder, with independent scientists raising concerns about cherry-picked evidence.
STAT News framed peptide self-injection as a case study in medical libertarianism: USADA banned BPC-157 in 2022 citing zero approval by any global regulatory authority, yet the compound remains widely available through "research chemical" suppliers.
A University of New South Wales review of GHK-Cu, BPC-157, and TB-500 found high-quality human evidence is absent — support rests on small, short-term, or animal studies. Flagged biological risks include potential stimulation of tumor growth, endocrine disruption, and infection from unsterile self-injection technique.

A Case Western Reserve study in Cancer Letters found NMN, NR, and NAM protect pancreatic cancer cells from three common chemotherapy drugs (oxaliplatin, 5-FU, gemcitabine) in lab and mouse models — by boosting cellular energy and reducing oxidative stress that chemotherapy relies on to kill cells. The authors are not flagging risk for healthy individuals but recommend cancer patients disclose supplementation to their oncologists.
A meta-analysis found NMN supplementation produces a modest reduction in diastolic blood pressure, with stronger systolic effects in adults 60 and older. Effect sizes are small; clinical significance remains unclear.
Niagen Bioscience partnered with the USP to establish the first official pharmacopeial monograph for nicotinamide riboside chloride — setting purity and identity standards for NR in the US supplement market for the first time.
A study in Aging Cell found that combining NMN with a PARP inhibitor activated SIRT3, suppressed cellular senescence, and improved musculoskeletal regeneration in aging models — suggesting the regenerative potential of NAD+ precursors may depend substantially on co-intervention context rather than NMN alone.

Get Longevity & Anti-Aging Science in your inbox